NEW DELHI: Drug firm Jubilant Life Sciences has received approval from the US health regulator to market Indomethacin capsule used for treating pains.
In a BSE filing, Jubilant Life Sciences said it “received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Indomethacin ER Capsule 75mg, which is a non-steriodal anti-inflammatory drug used for treatment of pain
Jubilant Life Sciences said as on June 30, 2015, it had a total of 815 filings for formulations of which 389 have been approved in various regions globally.
“This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe,” it added.
Jubilant Life Sciences Limited is a Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery Solutions. The Company provides offerings of Pharmaceutical and Life Sciences products and services across the value chain. It has 10 manufacturing facilities in India, US and Canada and a team of about 6,000 multicultural people across the globe.